Cancer Res: a new method for the treatment of breast cancer

September 24, 2018 / bioin / - a cytokine signal in some specific breast cancer stem cells can not only be used as a diagnostic tool for HER2 negative tumors, but also provide an effective therapeutic target Photo source: Cancer Res, a study by Dr Karolina palucka, Professor of JAK, and researchers from Baylor Institute of immunology, found that inflammation driven by IL1B (a member of the IL-1 cytokine family) is usually found in breast tumors, which can be an IL1 signal in female HER2 negative metastatic breast cancer "We found that IL1B in breast cancer promotes cancer promoting inflammation." Said palucka "This is associated with poor clinical outcomes We found that the use of the natural IL1 receptor antagonist anabolin can effectively target this signal in patients Anabolin has been widely used in the treatment of autoimmune and autoimmune diseases Researchers are also studying its effect as an adjuvant treatment to reduce inflammation in metastatic cancer, including metastatic colorectal cancer In the new study, 11 women with advanced metastatic HER2 negative breast cancer were treated with anabolin, and the researchers found that the expression of IL1B and other related signal factors decreased two weeks after treatment The researchers then treated the patient for four months with anabasin and standard chemotherapy The results showed that during the treatment period, the pain of some patients decreased and life therapy improved Three of them are still alive The research results were recently published in cancer research Dr Charles A dinarello, from the University of Colorado, Denver, anshutz medical school, published a review article in the same journal It was also he who discovered, cloned and characterized the basic biological information of IL-1 "This study represents the efforts of palucka and his colleagues in cancer research over the years." Dinarello wrote "Although it's great to know the risk of a signaling pathway and its corresponding prognosis, it's still necessary to explore relevant targeted therapies to really benefit patients In the case of tumor patients with IL1B signal, simply inhibiting IL1 is enough In fact, this is what this study has accomplished " Reference: Karolina palucka et al IL1 receiver antonist controls transcription signature of infection in patients with metastatic breath cancer Cancer research (2018) Doi: 10.1158/0008-5472